The ABL2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 hepatic adenocarcinoma line, designed for targeted disruption of the ABL2 gene. This product provides a heterogeneous pool of cells carrying diverse ABL2 loss-of-function mutations, enabling functional studies without the confounding effects of clonal variation. The polyclonal format is particularly suited for experiments requiring a population-level representation of gene disruption, such as pooled screening, signaling analysis, and migration assays, where consistency and reproducibility across a mixed genotype background are advantageous.
The SK-HEP-1 host cell line originates from a human liver adenocarcinoma and is widely utilized as a model for hepatocellular carcinoma (HCC) and cancer cell biology. Exhibiting an epithelial morphology, these cells retain many characteristics of malignant liver tissue, including robust migratory and invasive properties. SK-HEP-1 cells express integrins, receptor tyrosine kinases, and downstream effectors that are deregulated in liver cancer, making them a relevant system for investigating the molecular basis of HCC progression and metastasis.
ABL2, a non-receptor tyrosine kinase, functions as a key regulator of actin cytoskeleton remodeling, cell adhesion, and migration. It is activated downstream of integrin receptors, platelet-derived growth factor receptor (PDGFR), and ephrin receptors, and is modulated by Src family kinases and DNA damage signals. Once activated, ABL2 phosphorylates substrates including Cortactin, the WAVE complex, p120-catenin, Crk/CrkL, and Dok1, thereby orchestrating cytoskeletal dynamics. ABL2 interacts with scaffolding proteins such as ABI1/2, Nck, p130Cas, and Paxillin, and directly binds F-actin. These interactions link ABL2 to the Rac1 and RhoA GTPases, which in turn regulate PAK, WASP, and the Arp2/3 complex to control actin polymerization and cell protrusion formation.
In the context of SK-HEP-1 cells, ABL2 disruption is anticipated to impair actin-dependent processes critical for hepatocellular carcinoma cell invasion and metastasis. Knockout of ABL2 is expected to reduce phosphorylation of its direct targets, weaken adhesion turnover, and disrupt lamellipodia and filopodia dynamics. This loss-of-function model allows researchers to dissect ABL2-dependent pathways that contribute to liver cancer malignancy, and to evaluate the dependency of invasive behavior on integrin-to-ABL2 signaling. The model also provides a platform for testing small-molecule ABL kinase inhibitors in a relevant cancer background.
Key research applications include studying the role of ABL2 in hepatocarcinoma cell migration and invasion via wound healing and Transwell assays, screening ABL kinase inhibitors for efficacy, and investigating integrin-mediated signaling cascades in HCC. The polyclonal knockout cells are suitable for Western blot analysis of ABL2 and phospho-tyrosine substrates, immunofluorescence staining of the actin cytoskeleton with phalloidin, co-immunoprecipitation of ABL2 interaction partners, and phospho-signaling arrays to map network changes upon ABL2 loss. For further details or to discuss custom configurations, please contact Ascent Research.
